Skip to content

Coseal Surgical Sealant 934071Recalls & reported problems

Baxter Healthcare Corporation · Coseal Surgical Sealant (Coseal) is composed of two synthetic polyethylene glycols (PEGs), a dilute hydrogen chloride solution and a sodium phosphate/sodium carbonate solution. These components come in a kit that includes an applicator(s). At the time of administration, the mixed PEGs and solutions form a hydrogel that adheres to tissue, synthetic graft materials and covalently bonds to itself · Class 3 · Implant

All models of Coseal Surgical Sealant (2)

Data updated Oct 18, 2026 from official FDA records · Editorial policy

1 open recall names this device. See the recall details and contact the manufacturer or your healthcare provider.

Adverse event reports
2
Deaths reported
0
Injuries reported
2
Recalls naming it
1

Summary

The FDA's MAUDE database contains 2 adverse event reports that list this exact device (DI 05413765404627), received between Apr 9, 2024 and Jul 2, 2024 — classified as 2 injuries.

1 FDA recall record name this device's identifier, 1 still open.

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.

Reports received per month

Nov 2023: 0 reportsDec 2023: 0 reportsJan 2024: 0 reportsFeb 2024: 0 reportsMar 2024: 0 reportsApr 2024: 1 reportsMay 2024: 0 reportsJun 2024: 0 reportsJul 2024: 1 reportsAug 2024: 0 reportsSep 2024: 0 reportsOct 2024: 0 reportsNov 2024: 0 reportsDec 2024: 0 reportsJan 2025: 0 reportsFeb 2025: 0 reportsMar 2025: 0 reportsApr 2025: 0 reportsMay 2025: 0 reportsJun 2025: 0 reportsJul 2025: 0 reportsAug 2025: 0 reportsSep 2025: 0 reportsOct 2025: 0 reportsNov 2025: 0 reportsDec 2025: 0 reportsJan 2026: 0 reportsFeb 2026: 0 reportsMar 2026: 0 reportsApr 2026: 0 reportsMay 2026: 0 reportsJun 2026: 0 reportsJul 2026: 0 reportsAug 2026: 0 reportsSep 2026: 0 reportsOct 2026: 0 reports2024202520261
Last 36 months. The most recent month may be incomplete.

Recalls naming this device

  1. Dec 6, 2023Class IIOpen, Classified

    Cardiovascular Surgery marketing brochure (US-AS46-220001) that was distributed for the products listed below contains inaccurate content that does not align with some of the products Instructions for Use (IFU) or Prescribing Information (PI).

    Z-0657-2024 · Root cause: Under Investigation by firm · Recall details · FDA record ↗

Most reported problems

Device problems

  • Adverse Event Without Identified Device or Use Problem2

Patient problems

  • Cardiac Tamponade2
  • Pericardial Effusion1

Recent adverse event reports

The 2 most recent of 2 reports, in the reporter's own words as published by the FDA.

  • InjuryJul 2, 2024Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem

    FIVE DAYS PRIOR TO THE RECEIPT OF THIS REPORT, THE PATIENT UNDERWENT A THORACOTOMY (PULMONARY ARTERY BANDING) PROCEDURE WHEREIN COSEAL SURGICAL SEALANT WAS APPLIED. THREE DAYS LATER THE PATIENT DEVELOPED A TWO-STAGE PULSE ARRHYTHMIA UPON AWAKENING. ANALGESIA WAS ADDED AND THE PATIENT WAS MONITORED. CIRCULATION WAS STABLE. TWO DAYS LATER SEDATION WAS TERMINATED AND THE TWO STAGE PLUSE DID NOT REOCCUR. THE FOLLOWING DAY THE PATIENT WAS TRANSFERRED TO A GENERAL MEDICAL UNIT. AN ECHOCARDIOGRAM WAS PERFORMED, AND A SMALL AMOUNT OF PERICARDIAL FLUID WAS FOUND AROUND THE ENTIRE CIRCUMFERENCE OF THE HEART. DIASTOLIC DIMENSION IS LESS THAN 1MM. TWO DAYS AFTER THAT, A FOLLOW UP ECHOCARDIOGRAM WAS PERFORMED, AND A PERICARDIAL EFFUSION WAS OBSERVED AROUND THE ENTIRE HEART. THE DIASTOLIC DIMENSION WAS ABOUT 7 MM, WHICH HAD RAPIDLY INCREASED COMPARED TO THE DAY BEFORE YESTERDAY. EMERGENCY DRAINAGE WAS PERFORMED. A MEDIAN SUBCUTANEOUS INCISION OF ABOUT 4 CM WAS MADE TO REACH THE PERICARDIAL SAC AT THE DIAPHRAGMATIC PLANE, RESULTING IN A CLEAR RED PALE BLOODY PERICARDIAL EFFUSION. THE PERICARDIAL EFFUSION DRAINED APPROXIMATELY 35 ML. SINCE THERE WAS NO PERSISTENT BLEEDING IN THE PERICARDIAL SAC, A

    Patient problems: Cardiac Tamponade

    MAUDE report 19657698 ↗
  • InjuryApr 9, 2024Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem

    THE PATIENT UNDERWENT A PULMONARY ARTERY BANDING WHEREIN COSEAL SURGICAL SEALANT WAS APPLIED UTILIZING EASYSPRAY AND COSEAL SPRAY SET. THE PATIENT WAS ADMITTED TO THE PEDIATRIC INTENSIVE CARE UNIT. FOUR DAYS POSTOPERATIVE (POSTOP) AN ECHOCARDIOGRAM WAS PERFORMED, AND NO ABNORMALITIES WERE NOTED. BOTH THE INTRAPERICARDIAL AND MEDIASTINAL DRAINS WERE REMOVED. THE PATIENT WAS TRANSFERRED TO A GENERAL MEDICAL PEDIATRIC UNIT IN ¿STABLE CONDITION.¿ THE FOLLOWING DAY, AT 0100 SERUM EXUDATE WAS OBSERVED ORIGINATING FROM THE WOUND. TWO HOURS LATER, AN ECHOCARDIOGRAPHY SHOWED A SMALL AMOUNT OF PERICARDIAL FLUID ALL AROUND THE WOUND. THERE WAS A ¿POSSIBILITY OF LEAKING FLUID FROM THE SUTURE GAP IN THE WOUND;¿ HOWEVER, THE WOUND EDGE WAS NOT BROKEN OPEN AND WAS TEMPORARILY PROTECTED WITH A DRESSING AND FILM.¿ PREDONINE WAS STARTED AS ¿PERICARDIAL FLUID THERAPY.¿ SEVEN HOURS LATER, AN ECHOCARDIOGRAPHY SHOWED INCREASED PERICARDIAL EFFUSION AROUND THE ENTIRE CIRCUMFERENCE (DIASTOLIC 1.5-2.0 MM, SYSTOLIC 3.5 MM [UP TO 6 MM IN SOME AREAS]). SIX AND HALF HOURS LATER THE ECHOCARDIOGRAPHY WAS REEVALUATED, AND THE DETERIORATION WAS ASSESSED. THE PATIENT WAS DIAGNOSED WITH CARDIAC TAMPONADE DUE TO PERIC

    Patient problems: Cardiac Tamponade; Pericardial Effusion

    MAUDE report 19071312 ↗

Other Sealant,Polymerizing devices

All Sealant,Polymerizing devices →

Sources and updates

How reports and recalls are matched · Editorial policy · Report an error on this page